Dr Reddy’s Wants To Break Into Top Five In India
Expects China Market Uptick, India Sputnik V Go-Ahead In March
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
You may also be interested in...
Significant allocations for public health programs and vaccination are prominent features of India's budget for fiscal 2021-22, though execution of these plans will be critical. Pharma is also keenly tracking a proposed allocation to bolster the overall research ecosystem and opening up of the insurance sector to foreign ownership.
Financially stretched Wockhardt sells select branded generic business to Dr Reddy’s for $260m, bringing the curtains down on a much anticipated transaction.
New markets are opening up for Indian firms and China appears to be the flavor of the season, but gaining a strong foothold there is not expected to be even "half as easy" as in the US.